Trial: 201910014

AMulticenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Phase

III

Principal Investigator

Adkins, Douglas

Disease Site

Thyroid

Learn more about this study at: clinicaltrials.gov